ALT Altimmune Pharma: Wutah bathi EPS kuartalan

Altimmune, Inc. (ALT) relies on external contractors for testing and manufacturing, creating a strong operational dependency. Quarterly earnings per share (EPS) growth illustrates the profitability trend, where the current value of the indicator is 54.40. The launch of pemvidutide for obesity treatment remains the priority. The market expects management to secure strategic deals to ensure the successful commercialization of the product.

Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan Altimmune (ALT): kanggo periode 04.07.2022 - 12.11.2026

Ringkesan rincian data analitis Altimmune Pharma (ALT)

- rega saham lan prakiraan rega para ahli:

Rega saham Altimmune|ALT - Prakiraan konsensus analis

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar Altimmune Corp|ALT - Nilai Total Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Altimmune|ALT - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku altimmune.com|ALT - Aset Agregat Perusahaan

- indikator beban utang lan likuiditas:

Total Utang marang Modal Altimmune, Inc.|ALT - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Altimmune, Inc.|ALT - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Altimmune Corp|ALT - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Altimmune|Likuiditas cepet altimmune.com

- rincian bathi lan kelipatan pasar:

ALT - Bathi resik perusahaan|Bathi mangsa ngarep Altimmune, Inc.|ALT - Rasio rega pasar marang bathi resik|Pangali Forward P/E Altimmune Corp|ALT - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Altimmune Corp|ALT - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Altimmune|ALT - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan altimmune.com|ALT - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Altimmune, Inc.

Analisis kabeh metrik perusahaan:Altimmune, Inc.

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. This trend allows investors to assess the actual scaling speed of the business and avoid overpaying for the asset. Analyzing the quarterly EPS growth trend reveals the impact of capital expenditures on profitability. For Altimmune, Inc. (ALT), this is critical when hiring market access and clinical trial experts. Retaining the scientific core during aggressive management expansion directly determines the future profit trajectory.

Pesaing utama